The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial Invivoscribe Inc ...

Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD ...

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

These investments are anticipated to not only support market growth but also drive innovation, particularly in diagnostics and biomedical research, positioning South Korea as a key player in the ...

We often use the term “definitive phenotypes” in flow cytometry, which describes the least number of markers to define specific cell populations. Not too long ago, flow cytometry assays were limited ...

Beyond morphological assessment, MRD monitoring can offer a valuable addition for evaluating response status in paediatric AML. Our findings are of high clinical impact, given a more effective and ...

Management reiterated plans to initiate two Phase 3 trials under the KOMET-017 protocol for frontline AML in the second half of 2025. The trials will use MRD-negative CR and CR as primary ...

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, and an Operating Company of Danaher Corporation, revolutionizes spectral flow cytometry with the industry ...